Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells

被引：53

作者：

Long, ZF ^{[1
]}

Li, LP ^{[1
]}

Grooms, T ^{[1
]}

Lockey, C ^{[1
]}

Nader, K ^{[1
]}

Mychovsky, I ^{[1
]}

Mueller, S ^{[1
]}

Burimski, I ^{[1
]}

Ryan, P ^{[1
]}

Kikuchi, G ^{[1
]}

Ennist, D ^{[1
]}

Marcus, S ^{[1
]}

Otto, E ^{[1
]}

McGarrity, G ^{[1
]}

机构：

[1] Genet Therapy Inc, Gaithersburg, MD 20878 USA

来源：

HUMAN GENE THERAPY | 1998年 / 9卷 / 08期

关键词：

D O I：

10.1089/hum.1998.9.8-1165

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Patients with recurrent malignant brain cancer, who were receiving gene therapy by intracerebral injection of murine retroviral vector producer cells (VPCs), were monitored for the presence of replication-competent retrovirus (RCR), RCR sequences were not detected by polymerase chain reaction (PCR) in any of the 608 peripheral blood leukocyte (PBL) samples analyzed, Vector DNA sequences were detected transiently in PBL samples from a subset of 34 patients. Humoral immune responses to a retroviral core protein p30 and murine VPC were detected in some patients, most frequently in patients receiving repeated administrations of VPC, RCR was not detected in biological assays of PBLs from 41 patients who had either anti-retroviral antibodies in sera and/or vector DNA in PBLs. Our data suggest that in situ generation of RCR was not detected following intracerebral inoculation of VPCs in any of the 128 patients evaluated.

引用

页码：1165 / 1172

页数：8

共 25 条

[1] REPORT TO THE NIH-RECOMBINANT-DNA-ADVISORY-COMMITTEE ON MURINE REPLICATION-COMPETENT RETROVIRUS (RCR) ASSAYS (FEBRUARY 17, 1993) [J].